Phase 1 primary completion: A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Sponsor: Pfizer. Status: Active, not recruiting. Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma. NCT05355701.